Last checked at 29 Mar 2011 07:00
Tissue Regenix Appoints Ian Jefferson as Chief Financial Officer
YORK, 29 March 2011 - Tissue Regenix, the regenerative medical device company, today announces the appointment of Ian Jefferson as Chief Financial Officer (CFO). Ian will commence his appointment no later than 13 June 2011 and will replace the current CFO, Mike Bretherton, who will become a Non-Executive Director.
From 2008 to 2010 Ian was Chief Executive Officer (CEO) of COE Group Plc (COE) an AIM quoted designer, developer and manufacturer of integrated CCTV systems. Having initially joined as CFO in 2007 he became CEO in 2008, restructured the Group and successfully executed its sale to Digital Barriers Plc. Following the sale Ian remained at COE as Managing Director from where he joins Tissue Regenix.
Prior to COE, Ian held a number of senior finance positions within LSE-quoted companies, most recently as Group Financial Controller of 600 Group Plc. He has a comprehensive financial and operations background and extensive experience of organisational transformation and M&A. A qualified chartered accountant, Ian holds a BSc in Physics with Electronics from Manchester University and a MSc in Applied Radiation Physics from Birmingham University.
John Samuel, Chairman of Tissue Regenix, said: "I'd like to thank Mike for his work in the period following the reverse and I am delighted to announce Ian's appointment as CFO. Ian's experience and strong financial management skills will be invaluable as we prepare to enter the next phase in our developmental and commercial growth."
Further information:
Full Name: Ian David Jefferson
Age: 40
Current Directorships: None
Previous Directorships in last 5 years: COE Group Plc, COE Ltd, Timeload (UK) Ltd, Timeload Holdings Ltd, Timeload Local Ltd, Auction Ads Ltd, Jefferson Accountants Ltd
Ian Jefferson has confirmed that there is no further information to be disclosed in accordance with the requirements of Schedule Two (g) of the AIM rules.
Enquiries:
Financial Dynamics Ben Atwell / John Dineen |
+44 (0) 20 7831 3113 |
Tissue Regenix Group plc Antony Odell |
+44 (0) 1904 567 609 |
Peel Hunt LLP (Nominated Adviser) James Steel / Vijay Barathan |
+44 (0) 20 7418 8900 |
About Tissue Regenix
Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.
About dCELL® Technology
The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms.
Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).